NXgenPort Announces Collaboration with Mayo Clinic
News provided by
Share this article
Share this article
MINNEAPOLIS and VENTURA, Calif., May 25, 2021 /PRNewswire/ NXgenPort, a biomedical technology company developing products to provide doctors with remote patient monitoring, announced today that it has entered into a license agreement with Mayo Clinic to advance development and product testing efforts.
NXgenPort s medical device helps providers like Mayo Clinic monitor cancer patients at home with an implantable chemo-port catheter (patent pending). NXgenPort combines proven chemo-port efficacy with sensor technology to measure and remotely monitor early onset of complications by reporting and tracking patient response over the course of their treatment. According to the Chief Science Officer at NXgenPort, Dr. Rosanne Welcher, NXgenPort will bring the benefits of remote patient monitoring to cancer patients, who may have limited support between their trea
Mayo Clinic is ramping up activity in the remote patient monitoring arena. Its latest move is a collaboration with biomedical technology company NXgenPort, which will focus on an implantable catheter that can remotely monitor cancer patients for complications as they undergo treatment.